Marian Rewers
Concepts (927)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 391 | 2026 | 3836 | 20.830 |
Why?
| | Autoimmunity | 135 | 2026 | 927 | 12.090 |
Why?
| | Islets of Langerhans | 122 | 2026 | 829 | 11.750 |
Why?
| | Autoantibodies | 189 | 2026 | 1492 | 11.410 |
Why?
| | Celiac Disease | 54 | 2026 | 305 | 7.200 |
Why?
| | Genetic Predisposition to Disease | 97 | 2026 | 2423 | 4.390 |
Why?
| | Coronary Artery Disease | 34 | 2018 | 722 | 3.280 |
Why?
| | Diabetic Angiopathies | 28 | 2017 | 252 | 3.100 |
Why?
| | Child, Preschool | 211 | 2026 | 11772 | 3.000 |
Why?
| | HLA-DQ Antigens | 38 | 2025 | 173 | 2.970 |
Why?
| | Child | 243 | 2026 | 22771 | 2.830 |
Why?
| | Calcinosis | 23 | 2015 | 238 | 2.800 |
Why?
| | HLA-DR Antigens | 28 | 2021 | 223 | 2.670 |
Why?
| | Insulin Resistance | 55 | 2018 | 1234 | 2.560 |
Why?
| | Insulin | 75 | 2026 | 2501 | 2.460 |
Why?
| | Disease Progression | 83 | 2026 | 2862 | 2.410 |
Why?
| | Infant | 168 | 2026 | 10014 | 2.370 |
Why?
| | Risk Factors | 165 | 2026 | 10661 | 2.260 |
Why?
| | Diabetic Ketoacidosis | 16 | 2026 | 210 | 2.140 |
Why?
| | Humans | 513 | 2026 | 143806 | 2.140 |
Why?
| | Transglutaminases | 30 | 2026 | 158 | 2.050 |
Why?
| | Polymorphism, Single Nucleotide | 39 | 2026 | 2181 | 2.030 |
Why?
| | Blood Glucose | 38 | 2022 | 2318 | 2.010 |
Why?
| | Autoimmune Diseases | 17 | 2026 | 469 | 1.970 |
Why?
| | Genotype | 63 | 2026 | 1877 | 1.970 |
Why?
| | Male | 349 | 2026 | 71659 | 1.930 |
Why?
| | Prospective Studies | 101 | 2026 | 7915 | 1.900 |
Why?
| | Biomarkers | 50 | 2026 | 4242 | 1.890 |
Why?
| | Female | 357 | 2026 | 77403 | 1.870 |
Why?
| | Insulin Antibodies | 24 | 2026 | 103 | 1.860 |
Why?
| | Adolescent | 149 | 2026 | 22520 | 1.850 |
Why?
| | Mass Screening | 23 | 2026 | 1336 | 1.700 |
Why?
| | Glutamate Decarboxylase | 35 | 2025 | 166 | 1.650 |
Why?
| | Hyperglycemia | 11 | 2026 | 365 | 1.610 |
Why?
| | Diabetic Nephropathies | 19 | 2020 | 306 | 1.590 |
Why?
| | Insulin-Secreting Cells | 15 | 2023 | 389 | 1.480 |
Why?
| | Coronary Disease | 15 | 2010 | 373 | 1.440 |
Why?
| | Prediabetic State | 14 | 2023 | 255 | 1.410 |
Why?
| | Diet | 30 | 2026 | 1290 | 1.360 |
Why?
| | Case-Control Studies | 59 | 2026 | 3633 | 1.350 |
Why?
| | Follow-Up Studies | 66 | 2026 | 5319 | 1.280 |
Why?
| | HLA Antigens | 24 | 2025 | 232 | 1.210 |
Why?
| | Health Care Costs | 2 | 2025 | 421 | 1.200 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 10 | 2022 | 48 | 1.190 |
Why?
| | Glutens | 11 | 2023 | 59 | 1.160 |
Why?
| | Cohort Studies | 68 | 2026 | 5897 | 1.130 |
Why?
| | Diabetes Mellitus, Type 2 | 36 | 2025 | 2580 | 1.120 |
Why?
| | Fatty Acids, Omega-3 | 8 | 2020 | 142 | 1.090 |
Why?
| | Enterovirus Infections | 6 | 2023 | 174 | 1.060 |
Why?
| | HLA-DR3 Antigen | 17 | 2025 | 76 | 1.040 |
Why?
| | Adult | 161 | 2026 | 40083 | 1.040 |
Why?
| | Polymorphism, Genetic | 15 | 2019 | 626 | 1.030 |
Why?
| | Environment | 5 | 2018 | 344 | 1.000 |
Why?
| | DNA Methylation | 8 | 2026 | 668 | 0.990 |
Why?
| | Infant, Newborn | 66 | 2025 | 6382 | 0.970 |
Why?
| | H(+)-K(+)-Exchanging ATPase | 2 | 2017 | 8 | 0.960 |
Why?
| | Erythrocyte Membrane | 5 | 2015 | 52 | 0.950 |
Why?
| | HLA-DR4 Antigen | 17 | 2025 | 77 | 0.900 |
Why?
| | Atherosclerosis | 15 | 2018 | 407 | 0.900 |
Why?
| | Longitudinal Studies | 31 | 2026 | 3011 | 0.880 |
Why?
| | Colorado | 44 | 2024 | 4668 | 0.860 |
Why?
| | Middle Aged | 137 | 2025 | 35398 | 0.860 |
Why?
| | Age of Onset | 20 | 2026 | 549 | 0.860 |
Why?
| | Diabetes Complications | 7 | 2019 | 222 | 0.830 |
Why?
| | Incidence | 36 | 2022 | 2848 | 0.830 |
Why?
| | Albuminuria | 12 | 2016 | 186 | 0.830 |
Why?
| | Coronary Vessels | 8 | 2017 | 251 | 0.830 |
Why?
| | Enterovirus | 5 | 2019 | 85 | 0.820 |
Why?
| | Seroconversion | 7 | 2026 | 50 | 0.800 |
Why?
| | Vitamin D | 8 | 2026 | 401 | 0.790 |
Why?
| | Proportional Hazards Models | 26 | 2024 | 1294 | 0.790 |
Why?
| | Vascular Calcification | 9 | 2018 | 111 | 0.770 |
Why?
| | Predictive Value of Tests | 25 | 2019 | 2087 | 0.740 |
Why?
| | Young Adult | 53 | 2026 | 13992 | 0.720 |
Why?
| | Glucose Tolerance Test | 26 | 2022 | 376 | 0.700 |
Why?
| | C-Peptide | 7 | 2025 | 179 | 0.680 |
Why?
| | Breast Feeding | 18 | 2021 | 445 | 0.670 |
Why?
| | Inflammation | 10 | 2026 | 2882 | 0.670 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 12 | 2025 | 54 | 0.670 |
Why?
| | Haplotypes | 15 | 2026 | 496 | 0.670 |
Why?
| | Genetic Testing | 8 | 2019 | 474 | 0.660 |
Why?
| | Fatty Acids | 6 | 2021 | 453 | 0.650 |
Why?
| | Calcium | 8 | 2023 | 1183 | 0.650 |
Why?
| | Zinc Transporter 8 | 8 | 2025 | 63 | 0.640 |
Why?
| | Blood Glucose Self-Monitoring | 6 | 2022 | 719 | 0.630 |
Why?
| | Antibodies, Viral | 6 | 2023 | 668 | 0.620 |
Why?
| | Autoantigens | 9 | 2025 | 427 | 0.610 |
Why?
| | Early Diagnosis | 7 | 2025 | 247 | 0.570 |
Why?
| | Prevalence | 23 | 2024 | 2831 | 0.560 |
Why?
| | Infant Nutritional Physiological Phenomena | 5 | 2021 | 145 | 0.560 |
Why?
| | Uric Acid | 6 | 2018 | 163 | 0.560 |
Why?
| | GTP-Binding Proteins | 7 | 2024 | 151 | 0.550 |
Why?
| | Cross-Sectional Studies | 36 | 2025 | 5760 | 0.550 |
Why?
| | Body Mass Index | 23 | 2025 | 2432 | 0.540 |
Why?
| | Germany | 12 | 2024 | 139 | 0.530 |
Why?
| | Logistic Models | 24 | 2017 | 2108 | 0.530 |
Why?
| | Infant Food | 7 | 2018 | 65 | 0.530 |
Why?
| | Adiponectin | 5 | 2016 | 244 | 0.510 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2016 | 97 | 0.510 |
Why?
| | Smoking | 9 | 2025 | 1580 | 0.510 |
Why?
| | Sensitivity and Specificity | 22 | 2026 | 1985 | 0.510 |
Why?
| | Edible Grain | 4 | 2008 | 47 | 0.510 |
Why?
| | Fibrinogen | 5 | 2019 | 179 | 0.500 |
Why?
| | Finland | 16 | 2025 | 82 | 0.500 |
Why?
| | Monitoring, Physiologic | 2 | 2009 | 289 | 0.490 |
Why?
| | Metabolomics | 5 | 2021 | 715 | 0.490 |
Why?
| | Glomerular Filtration Rate | 15 | 2020 | 778 | 0.490 |
Why?
| | Arteriosclerosis | 17 | 2004 | 83 | 0.490 |
Why?
| | Age Factors | 38 | 2026 | 3330 | 0.490 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2013 | 441 | 0.470 |
Why?
| | Genome-Wide Association Study | 10 | 2026 | 1452 | 0.470 |
Why?
| | Hypoglycemia | 5 | 2014 | 473 | 0.470 |
Why?
| | Triglycerides | 13 | 2020 | 517 | 0.460 |
Why?
| | Lipids | 5 | 2019 | 704 | 0.460 |
Why?
| | Hypertension | 11 | 2021 | 1261 | 0.450 |
Why?
| | Milk | 7 | 2017 | 124 | 0.450 |
Why?
| | Luminescent Measurements | 4 | 2021 | 76 | 0.450 |
Why?
| | Environmental Exposure | 4 | 2025 | 586 | 0.440 |
Why?
| | Prenatal Exposure Delayed Effects | 7 | 2025 | 680 | 0.440 |
Why?
| | Probiotics | 3 | 2022 | 60 | 0.440 |
Why?
| | C-Reactive Protein | 5 | 2018 | 418 | 0.440 |
Why?
| | Helicobacter Infections | 1 | 2014 | 29 | 0.430 |
Why?
| | Helicobacter pylori | 1 | 2014 | 44 | 0.430 |
Why?
| | Risk | 17 | 2020 | 906 | 0.420 |
Why?
| | Respiratory Tract Infections | 5 | 2025 | 389 | 0.420 |
Why?
| | Antibodies | 5 | 2024 | 402 | 0.410 |
Why?
| | Prognosis | 18 | 2026 | 4162 | 0.410 |
Why?
| | Micronutrients | 3 | 2026 | 95 | 0.410 |
Why?
| | Time Factors | 21 | 2018 | 7040 | 0.410 |
Why?
| | Asymptomatic Diseases | 3 | 2023 | 98 | 0.410 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2014 | 54 | 0.410 |
Why?
| | Inflammation Mediators | 3 | 2026 | 510 | 0.410 |
Why?
| | Dietary Supplements | 7 | 2024 | 587 | 0.400 |
Why?
| | Fatty Acid Desaturases | 1 | 2013 | 31 | 0.400 |
Why?
| | Sweden | 13 | 2024 | 110 | 0.400 |
Why?
| | Immunogenetics | 1 | 2013 | 7 | 0.400 |
Why?
| | Dyslipidemias | 4 | 2015 | 181 | 0.400 |
Why?
| | Alleles | 14 | 2021 | 893 | 0.390 |
Why?
| | Glucose Clamp Technique | 8 | 2020 | 198 | 0.390 |
Why?
| | Risk Assessment | 17 | 2021 | 3582 | 0.390 |
Why?
| | Proteomics | 6 | 2025 | 1162 | 0.390 |
Why?
| | United States | 35 | 2025 | 15584 | 0.380 |
Why?
| | HLA-D Antigens | 5 | 2019 | 30 | 0.380 |
Why?
| | Bacteriophages | 2 | 2025 | 110 | 0.380 |
Why?
| | Dietary Fats | 3 | 2014 | 304 | 0.380 |
Why?
| | Child Nutritional Physiological Phenomena | 4 | 2019 | 107 | 0.370 |
Why?
| | Oxylipins | 3 | 2023 | 46 | 0.370 |
Why?
| | Cost-Benefit Analysis | 4 | 2026 | 624 | 0.370 |
Why?
| | Fasting | 12 | 2015 | 284 | 0.370 |
Why?
| | Genetic Variation | 4 | 2026 | 1010 | 0.360 |
Why?
| | Epitopes | 6 | 2025 | 489 | 0.360 |
Why?
| | Vitamin D Deficiency | 2 | 2011 | 188 | 0.360 |
Why?
| | Lipoproteins | 4 | 2015 | 163 | 0.360 |
Why?
| | Apolipoproteins A | 2 | 2006 | 18 | 0.360 |
Why?
| | Ascorbic Acid | 4 | 2023 | 180 | 0.350 |
Why?
| | Addison Disease | 6 | 2012 | 39 | 0.350 |
Why?
| | Major Histocompatibility Complex | 6 | 2026 | 233 | 0.350 |
Why?
| | Liver | 3 | 2012 | 1869 | 0.340 |
Why?
| | Adipocytes | 1 | 2012 | 222 | 0.340 |
Why?
| | Fetal Blood | 6 | 2021 | 339 | 0.340 |
Why?
| | Sex Factors | 20 | 2020 | 2096 | 0.330 |
Why?
| | Life Style | 5 | 2015 | 485 | 0.330 |
Why?
| | Dietary Proteins | 4 | 2019 | 135 | 0.330 |
Why?
| | Hypolipidemic Agents | 2 | 2010 | 95 | 0.330 |
Why?
| | Hypoglycemic Agents | 8 | 2020 | 1403 | 0.330 |
Why?
| | Cholesterol, HDL | 8 | 2015 | 197 | 0.330 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 724 | 0.320 |
Why?
| | Plant Proteins | 1 | 2011 | 111 | 0.320 |
Why?
| | Precision Medicine | 1 | 2014 | 446 | 0.320 |
Why?
| | Epidemics | 1 | 2011 | 95 | 0.320 |
Why?
| | Research | 2 | 2013 | 439 | 0.310 |
Why?
| | Surveys and Questionnaires | 17 | 2024 | 6033 | 0.310 |
Why?
| | Eating | 5 | 2023 | 397 | 0.310 |
Why?
| | Patient Education as Topic | 2 | 2005 | 783 | 0.310 |
Why?
| | Blood Proteins | 3 | 2017 | 247 | 0.310 |
Why?
| | Steroid 21-Hydroxylase | 5 | 2012 | 27 | 0.310 |
Why?
| | Cesarean Section | 2 | 2024 | 214 | 0.310 |
Why?
| | HLA-DQ beta-Chains | 12 | 2019 | 59 | 0.310 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2025 | 1130 | 0.300 |
Why?
| | CTLA-4 Antigen | 5 | 2017 | 105 | 0.300 |
Why?
| | Cystatin C | 6 | 2014 | 65 | 0.300 |
Why?
| | Obesity | 12 | 2015 | 3045 | 0.300 |
Why?
| | Family Health | 8 | 2017 | 197 | 0.300 |
Why?
| | Clinical Trials as Topic | 3 | 2009 | 1044 | 0.300 |
Why?
| | Multivariate Analysis | 10 | 2016 | 1511 | 0.300 |
Why?
| | Sex Distribution | 6 | 2011 | 383 | 0.290 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 38 | 0.290 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 736 | 0.290 |
Why?
| | Rotavirus | 2 | 2016 | 20 | 0.290 |
Why?
| | Antigens, CD | 2 | 2009 | 549 | 0.280 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.280 |
Why?
| | Feces | 7 | 2025 | 496 | 0.280 |
Why?
| | Europe | 11 | 2021 | 410 | 0.270 |
Why?
| | Diabetes Mellitus | 8 | 2009 | 1090 | 0.270 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.270 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.270 |
Why?
| | Adiposity | 7 | 2020 | 532 | 0.270 |
Why?
| | Epigenesis, Genetic | 4 | 2026 | 686 | 0.260 |
Why?
| | Reference Values | 10 | 2012 | 811 | 0.260 |
Why?
| | Seroepidemiologic Studies | 4 | 2023 | 171 | 0.260 |
Why?
| | Pregnancy | 18 | 2025 | 7164 | 0.260 |
Why?
| | Tomography, X-Ray Computed | 12 | 2018 | 2779 | 0.260 |
Why?
| | Diet, Gluten-Free | 3 | 2024 | 56 | 0.260 |
Why?
| | Proteome | 2 | 2025 | 495 | 0.260 |
Why?
| | Gene-Environment Interaction | 5 | 2024 | 191 | 0.260 |
Why?
| | Iron | 3 | 2023 | 346 | 0.260 |
Why?
| | Survival Analysis | 4 | 2021 | 1332 | 0.250 |
Why?
| | Glycopeptides | 2 | 2018 | 44 | 0.250 |
Why?
| | Adipose Tissue | 4 | 2018 | 654 | 0.250 |
Why?
| | Metabolome | 2 | 2020 | 374 | 0.250 |
Why?
| | HLA-DRB1 Chains | 8 | 2019 | 111 | 0.250 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.250 |
Why?
| | Exercise | 4 | 2023 | 2165 | 0.250 |
Why?
| | Rotavirus Infections | 1 | 2006 | 39 | 0.250 |
Why?
| | Histocompatibility Antigens Class I | 5 | 2011 | 208 | 0.250 |
Why?
| | RNA, Viral | 3 | 2019 | 704 | 0.250 |
Why?
| | Patient Compliance | 3 | 2023 | 617 | 0.240 |
Why?
| | Apolipoproteins C | 1 | 2006 | 4 | 0.240 |
Why?
| | Remission Induction | 2 | 2004 | 306 | 0.240 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 198 | 0.240 |
Why?
| | Overweight | 3 | 2021 | 598 | 0.240 |
Why?
| | HLA-DR alpha-Chains | 1 | 2026 | 5 | 0.240 |
Why?
| | Complement C4a | 1 | 2026 | 9 | 0.240 |
Why?
| | Regression Analysis | 15 | 2014 | 1013 | 0.240 |
Why?
| | Contraception | 1 | 2008 | 166 | 0.240 |
Why?
| | Infant Formula | 3 | 2019 | 71 | 0.240 |
Why?
| | Protein Tyrosine Phosphatases | 7 | 2006 | 168 | 0.240 |
Why?
| | Cardiovascular Diseases | 8 | 2018 | 2114 | 0.230 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 66 | 0.230 |
Why?
| | Quantitative Trait Loci | 2 | 2025 | 368 | 0.230 |
Why?
| | Chromosome Mapping | 4 | 2025 | 517 | 0.230 |
Why?
| | Carotid Arteries | 5 | 1998 | 202 | 0.230 |
Why?
| | Hypersensitivity, Immediate | 1 | 2025 | 41 | 0.230 |
Why?
| | Gene Frequency | 10 | 2020 | 492 | 0.230 |
Why?
| | Aged | 45 | 2021 | 25356 | 0.230 |
Why?
| | Maternal Age | 3 | 2004 | 129 | 0.230 |
Why?
| | Diet Records | 4 | 2019 | 84 | 0.230 |
Why?
| | Proinsulin | 3 | 2014 | 52 | 0.230 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2025 | 15 | 0.220 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2011 | 367 | 0.220 |
Why?
| | Glucose Intolerance | 7 | 2013 | 146 | 0.220 |
Why?
| | Apolipoproteins | 3 | 2014 | 36 | 0.220 |
Why?
| | Tobacco Smoke Pollution | 4 | 2019 | 238 | 0.220 |
Why?
| | Plasminogen Activator Inhibitor 1 | 6 | 2017 | 89 | 0.220 |
Why?
| | Introns | 1 | 2026 | 255 | 0.220 |
Why?
| | Abdominal Wall | 1 | 2004 | 27 | 0.220 |
Why?
| | Mass Spectrometry | 4 | 2025 | 741 | 0.220 |
Why?
| | Linear Models | 7 | 2016 | 860 | 0.220 |
Why?
| | Docosahexaenoic Acids | 3 | 2021 | 85 | 0.220 |
Why?
| | Immunotherapy | 1 | 2009 | 659 | 0.220 |
Why?
| | Health Surveys | 3 | 2018 | 512 | 0.220 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 516 | 0.210 |
Why?
| | Hyperlipidemias | 1 | 2005 | 127 | 0.210 |
Why?
| | Immunoglobulin A | 6 | 2024 | 218 | 0.210 |
Why?
| | Fever | 1 | 2025 | 311 | 0.210 |
Why?
| | Bone Density | 2 | 2020 | 503 | 0.210 |
Why?
| | Delivery, Obstetric | 2 | 2004 | 162 | 0.210 |
Why?
| | Vitamin B Complex | 1 | 2024 | 40 | 0.210 |
Why?
| | Animals | 26 | 2022 | 38068 | 0.200 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 55 | 0.200 |
Why?
| | Coronary Angiography | 2 | 2014 | 318 | 0.200 |
Why?
| | Seasons | 5 | 2024 | 556 | 0.200 |
Why?
| | Haptoglobins | 3 | 2013 | 63 | 0.200 |
Why?
| | Peptide Library | 1 | 2024 | 95 | 0.200 |
Why?
| | Alanine Transaminase | 2 | 2015 | 154 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2026 | 856 | 0.200 |
Why?
| | Birth Weight | 4 | 2016 | 521 | 0.200 |
Why?
| | Iron Overload | 1 | 2023 | 19 | 0.200 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 389 | 0.200 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 162 | 0.190 |
Why?
| | Child Development | 2 | 2020 | 507 | 0.190 |
Why?
| | Muscle, Skeletal | 2 | 2018 | 1789 | 0.190 |
Why?
| | Cytokines | 6 | 2026 | 2099 | 0.190 |
Why?
| | Virus Diseases | 4 | 2021 | 218 | 0.190 |
Why?
| | ROC Curve | 4 | 2019 | 603 | 0.190 |
Why?
| | Ketone Bodies | 2 | 2014 | 14 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 4 | 2018 | 922 | 0.190 |
Why?
| | Alcohol Drinking | 1 | 2009 | 853 | 0.180 |
Why?
| | Costs and Cost Analysis | 2 | 2020 | 220 | 0.180 |
Why?
| | Complement System Proteins | 1 | 2025 | 313 | 0.180 |
Why?
| | Lipid Metabolism | 2 | 2019 | 524 | 0.180 |
Why?
| | Pediatrics | 4 | 2020 | 1127 | 0.180 |
Why?
| | Diabetic Retinopathy | 4 | 2016 | 210 | 0.180 |
Why?
| | Mothers | 4 | 2021 | 784 | 0.180 |
Why?
| | Influenza, Human | 2 | 2022 | 636 | 0.180 |
Why?
| | Peptides | 3 | 2024 | 981 | 0.180 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 450 | 0.180 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2021 | 182 | 0.180 |
Why?
| | Blood Pressure | 9 | 2014 | 1756 | 0.180 |
Why?
| | Age Distribution | 5 | 2011 | 398 | 0.180 |
Why?
| | Odds Ratio | 6 | 2015 | 1060 | 0.180 |
Why?
| | Dietary Approaches To Stop Hypertension | 1 | 2021 | 13 | 0.180 |
Why?
| | Lipase | 1 | 2002 | 74 | 0.180 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2021 | 48 | 0.170 |
Why?
| | Monitoring, Ambulatory | 2 | 2014 | 90 | 0.170 |
Why?
| | Glycerol | 2 | 2012 | 90 | 0.170 |
Why?
| | Parents | 6 | 2023 | 1457 | 0.170 |
Why?
| | Receptors, Calcitriol | 2 | 2012 | 55 | 0.170 |
Why?
| | Reproducibility of Results | 9 | 2021 | 3381 | 0.170 |
Why?
| | T-Lymphocytes | 3 | 2025 | 2036 | 0.170 |
Why?
| | Growth | 2 | 2016 | 52 | 0.170 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1263 | 0.170 |
Why?
| | White Matter | 1 | 2023 | 146 | 0.170 |
Why?
| | Body Height | 3 | 2014 | 208 | 0.170 |
Why?
| | Polysaccharides | 2 | 2022 | 88 | 0.170 |
Why?
| | Gestational Age | 3 | 2020 | 973 | 0.170 |
Why?
| | Gastroenteritis | 2 | 2016 | 67 | 0.170 |
Why?
| | F2-Isoprostanes | 2 | 2015 | 21 | 0.170 |
Why?
| | Bacteria | 2 | 2025 | 888 | 0.170 |
Why?
| | Luminescence | 3 | 2016 | 38 | 0.170 |
Why?
| | HLA-B8 Antigen | 4 | 2012 | 11 | 0.160 |
Why?
| | Vitamins | 2 | 2020 | 181 | 0.160 |
Why?
| | Ketosis | 1 | 2020 | 12 | 0.160 |
Why?
| | Influenza Vaccines | 2 | 2017 | 553 | 0.160 |
Why?
| | Genomics | 2 | 2021 | 832 | 0.160 |
Why?
| | Dietary Sucrose | 1 | 2020 | 48 | 0.160 |
Why?
| | Dietary Carbohydrates | 2 | 2015 | 152 | 0.160 |
Why?
| | Neonatal Screening | 4 | 2020 | 180 | 0.160 |
Why?
| | Disease Susceptibility | 6 | 2020 | 354 | 0.160 |
Why?
| | Biopsy | 5 | 2017 | 1083 | 0.160 |
Why?
| | Mannose | 1 | 2019 | 23 | 0.160 |
Why?
| | Sugars | 1 | 2020 | 42 | 0.160 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 22 | 0.160 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 113 | 0.160 |
Why?
| | Mice, Inbred NOD | 5 | 2015 | 611 | 0.160 |
Why?
| | Life Change Events | 1 | 2021 | 152 | 0.150 |
Why?
| | Energy Intake | 5 | 2023 | 513 | 0.150 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 80 | 0.150 |
Why?
| | Interferon-gamma | 2 | 2021 | 791 | 0.150 |
Why?
| | Phospholipids | 1 | 2021 | 212 | 0.150 |
Why?
| | Developing Countries | 2 | 1993 | 311 | 0.150 |
Why?
| | Metabolic Clearance Rate | 3 | 2014 | 117 | 0.150 |
Why?
| | Kidney | 2 | 2018 | 1507 | 0.150 |
Why?
| | Epidemiologic Methods | 4 | 2014 | 94 | 0.150 |
Why?
| | Oxidative Stress | 3 | 2017 | 1376 | 0.150 |
Why?
| | Cation Transport Proteins | 3 | 2011 | 116 | 0.150 |
Why?
| | Apolipoproteins B | 2 | 2015 | 45 | 0.150 |
Why?
| | Iodide Peroxidase | 5 | 2025 | 34 | 0.150 |
Why?
| | Measles | 1 | 2019 | 48 | 0.150 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 61 | 0.150 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2003 | 422 | 0.150 |
Why?
| | Glycosuria | 2 | 2009 | 10 | 0.150 |
Why?
| | Fatty Acids, Omega-6 | 4 | 2020 | 48 | 0.150 |
Why?
| | Butyrates | 1 | 2019 | 68 | 0.150 |
Why?
| | Cotinine | 1 | 2019 | 78 | 0.150 |
Why?
| | Antibodies, Bacterial | 1 | 2019 | 146 | 0.150 |
Why?
| | Uromodulin | 1 | 2018 | 20 | 0.150 |
Why?
| | Genes, MHC Class II | 3 | 2012 | 76 | 0.150 |
Why?
| | Genetic Markers | 4 | 2013 | 345 | 0.140 |
Why?
| | Cholesterol | 5 | 2014 | 404 | 0.140 |
Why?
| | Mexican Americans | 3 | 2014 | 114 | 0.140 |
Why?
| | Health Expenditures | 1 | 2020 | 196 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2021 | 258 | 0.140 |
Why?
| | HLA-DP beta-Chains | 3 | 2015 | 90 | 0.140 |
Why?
| | Models, Biological | 5 | 2019 | 1831 | 0.140 |
Why?
| | Self Report | 3 | 2020 | 878 | 0.140 |
Why?
| | Squalene | 1 | 2017 | 8 | 0.140 |
Why?
| | HLA-DR2 Antigen | 2 | 2012 | 7 | 0.140 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.140 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 46 | 0.140 |
Why?
| | Amino Acid Sequence | 6 | 2024 | 2167 | 0.140 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 162 | 0.130 |
Why?
| | Phenotype | 8 | 2024 | 3209 | 0.130 |
Why?
| | Antipyretics | 1 | 2017 | 5 | 0.130 |
Why?
| | Cost of Illness | 1 | 2020 | 319 | 0.130 |
Why?
| | Feeding Behavior | 3 | 2013 | 688 | 0.130 |
Why?
| | Immune Tolerance | 1 | 2019 | 384 | 0.130 |
Why?
| | Radioimmunoassay | 6 | 2016 | 168 | 0.130 |
Why?
| | Blood Cell Count | 1 | 2017 | 52 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2017 | 1794 | 0.130 |
Why?
| | Immunologic Memory | 1 | 2019 | 365 | 0.130 |
Why?
| | Immunization | 1 | 1999 | 404 | 0.130 |
Why?
| | Body Composition | 3 | 2020 | 711 | 0.130 |
Why?
| | Rheumatoid Factor | 3 | 2007 | 176 | 0.130 |
Why?
| | Kidney Diseases | 2 | 2012 | 416 | 0.130 |
Why?
| | Models, Genetic | 2 | 2017 | 593 | 0.130 |
Why?
| | Osteoporosis | 1 | 2020 | 244 | 0.130 |
Why?
| | Genetic Loci | 3 | 2015 | 279 | 0.130 |
Why?
| | Rural Health | 2 | 2002 | 85 | 0.130 |
Why?
| | Poland | 4 | 2010 | 35 | 0.130 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 1 | 2017 | 60 | 0.120 |
Why?
| | Milk Proteins | 1 | 1996 | 35 | 0.120 |
Why?
| | Toxins, Biological | 1 | 2016 | 12 | 0.120 |
Why?
| | Patient Care Planning | 2 | 2015 | 162 | 0.120 |
Why?
| | Homozygote | 5 | 2014 | 201 | 0.120 |
Why?
| | Arachidonic Acid | 2 | 2021 | 107 | 0.120 |
Why?
| | Immunoglobulin G | 4 | 2021 | 898 | 0.120 |
Why?
| | Models, Theoretical | 2 | 2017 | 588 | 0.120 |
Why?
| | Vitamin B 12 | 1 | 2017 | 125 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1023 | 0.120 |
Why?
| | Body Weight | 3 | 2016 | 1003 | 0.120 |
Why?
| | Hygiene | 1 | 2016 | 29 | 0.120 |
Why?
| | HLA-A1 Antigen | 2 | 2006 | 4 | 0.120 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 7 | 2006 | 44 | 0.120 |
Why?
| | HLA-DP Antigens | 2 | 2007 | 32 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 78 | 0.120 |
Why?
| | Diet Surveys | 4 | 2021 | 93 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2017 | 126 | 0.120 |
Why?
| | Polymerase Chain Reaction | 5 | 2011 | 1062 | 0.120 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.120 |
Why?
| | Feeding Methods | 1 | 2015 | 6 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1560 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 763 | 0.120 |
Why?
| | Histocompatibility Testing | 6 | 2017 | 122 | 0.110 |
Why?
| | Complement C3 | 1 | 2016 | 190 | 0.110 |
Why?
| | Medical Records | 2 | 2007 | 185 | 0.110 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2018 | 639 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 272 | 0.110 |
Why?
| | Erythrocytes | 1 | 2021 | 708 | 0.110 |
Why?
| | Stress, Psychological | 2 | 2021 | 1137 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 551 | 0.110 |
Why?
| | Dietary Fiber | 1 | 2015 | 58 | 0.110 |
Why?
| | Carbohydrates | 1 | 2015 | 67 | 0.110 |
Why?
| | Genetic Association Studies | 4 | 2020 | 378 | 0.110 |
Why?
| | Child Day Care Centers | 1 | 2015 | 44 | 0.110 |
Why?
| | Oxygen | 1 | 2020 | 998 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 61 | 0.110 |
Why?
| | International Agencies | 1 | 2014 | 32 | 0.110 |
Why?
| | Up-Regulation | 2 | 2016 | 863 | 0.110 |
Why?
| | Gram-Positive Bacteria | 1 | 2014 | 48 | 0.110 |
Why?
| | Fructosamine | 1 | 2014 | 15 | 0.110 |
Why?
| | Video Recording | 2 | 2015 | 207 | 0.110 |
Why?
| | Dairy Products | 1 | 2014 | 30 | 0.110 |
Why?
| | Health Records, Personal | 1 | 2014 | 29 | 0.110 |
Why?
| | Carotid Artery Diseases | 3 | 2000 | 64 | 0.110 |
Why?
| | Societies, Scientific | 1 | 2014 | 50 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2015 | 288 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 29 | 0.110 |
Why?
| | Acetaminophen | 1 | 2017 | 264 | 0.110 |
Why?
| | Gram-Negative Bacteria | 1 | 2014 | 80 | 0.110 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2944 | 0.110 |
Why?
| | Bias | 1 | 2015 | 208 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 352 | 0.100 |
Why?
| | Renal Insufficiency | 1 | 2016 | 171 | 0.100 |
Why?
| | Eicosapentaenoic Acid | 1 | 2013 | 36 | 0.100 |
Why?
| | Cholesterol, Dietary | 1 | 2013 | 15 | 0.100 |
Why?
| | Hemodynamics | 1 | 2018 | 1117 | 0.100 |
Why?
| | Gene Expression | 3 | 2021 | 1505 | 0.100 |
Why?
| | Eggs | 1 | 2013 | 28 | 0.100 |
Why?
| | Siblings | 3 | 2018 | 217 | 0.100 |
Why?
| | Phosphates | 1 | 2014 | 178 | 0.100 |
Why?
| | Creatinine | 4 | 2018 | 499 | 0.100 |
Why?
| | Research Support as Topic | 1 | 2013 | 81 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 330 | 0.100 |
Why?
| | Biological Specimen Banks | 1 | 2013 | 99 | 0.100 |
Why?
| | Heart Rate | 3 | 2010 | 848 | 0.100 |
Why?
| | Hypoxia | 1 | 2020 | 1185 | 0.100 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 13 | 0.100 |
Why?
| | Mice | 11 | 2022 | 18414 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2015 | 165 | 0.090 |
Why?
| | Monoamine Oxidase | 1 | 2012 | 29 | 0.090 |
Why?
| | Anesthesiology | 1 | 2015 | 173 | 0.090 |
Why?
| | Organizational Innovation | 1 | 2013 | 128 | 0.090 |
Why?
| | Chromosomes, Human, Pair 2 | 2 | 2009 | 28 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2023 | 727 | 0.090 |
Why?
| | History, 21st Century | 1 | 2013 | 220 | 0.090 |
Why?
| | Sex Characteristics | 7 | 2015 | 790 | 0.090 |
Why?
| | Epistasis, Genetic | 1 | 2012 | 67 | 0.090 |
Why?
| | Stomach | 1 | 2012 | 117 | 0.090 |
Why?
| | CpG Islands | 2 | 2023 | 166 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2022 | 861 | 0.090 |
Why?
| | Pilot Projects | 4 | 2023 | 1839 | 0.090 |
Why?
| | Specimen Handling | 1 | 2013 | 181 | 0.090 |
Why?
| | Interleukin-4 | 2 | 2005 | 216 | 0.090 |
Why?
| | History, 20th Century | 1 | 2013 | 328 | 0.090 |
Why?
| | Intestine, Small | 2 | 2005 | 159 | 0.090 |
Why?
| | Nuclear Family | 2 | 2009 | 56 | 0.090 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 108 | 0.090 |
Why?
| | Hyperinsulinism | 2 | 2010 | 115 | 0.090 |
Why?
| | Intestines | 1 | 2014 | 357 | 0.090 |
Why?
| | Calcifediol | 1 | 2011 | 32 | 0.090 |
Why?
| | Lymphocytes | 1 | 2014 | 398 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 894 | 0.090 |
Why?
| | Pedigree | 4 | 2017 | 513 | 0.090 |
Why?
| | Primary Prevention | 1 | 2013 | 202 | 0.090 |
Why?
| | Patient Selection | 3 | 2011 | 692 | 0.090 |
Why?
| | Gliadin | 2 | 2009 | 12 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1254 | 0.090 |
Why?
| | Toll-Like Receptors | 1 | 2012 | 189 | 0.090 |
Why?
| | HLA-B Antigens | 1 | 2011 | 57 | 0.080 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2011 | 23 | 0.080 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 15 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2011 | 161 | 0.080 |
Why?
| | Interleukin-2 | 1 | 2012 | 451 | 0.080 |
Why?
| | Thyroglobulin | 3 | 2025 | 30 | 0.080 |
Why?
| | Vascular Diseases | 2 | 2013 | 246 | 0.080 |
Why?
| | Vaccines | 1 | 2016 | 410 | 0.080 |
Why?
| | Viruses | 1 | 2013 | 164 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2057 | 0.080 |
Why?
| | Endocrine Cells | 1 | 2010 | 6 | 0.080 |
Why?
| | Food, Fortified | 1 | 2010 | 43 | 0.080 |
Why?
| | Weight Gain | 2 | 2011 | 550 | 0.080 |
Why?
| | Linkage Disequilibrium | 4 | 2015 | 254 | 0.080 |
Why?
| | Gastrointestinal Diseases | 1 | 2012 | 211 | 0.080 |
Why?
| | Decision Support Techniques | 2 | 2013 | 445 | 0.080 |
Why?
| | Milk, Human | 3 | 2018 | 172 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2012 | 392 | 0.080 |
Why?
| | Myocardial Infarction | 2 | 1994 | 1073 | 0.080 |
Why?
| | Nutrition Assessment | 2 | 2015 | 92 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2010 | 158 | 0.080 |
Why?
| | Microbiota | 2 | 2014 | 761 | 0.080 |
Why?
| | Lymphocyte Activation | 1 | 2014 | 1143 | 0.080 |
Why?
| | Family | 5 | 2018 | 683 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 140 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 589 | 0.080 |
Why?
| | Socioeconomic Factors | 5 | 2017 | 1326 | 0.080 |
Why?
| | RNA | 1 | 2016 | 933 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2002 | 1177 | 0.080 |
Why?
| | Quality Control | 3 | 2013 | 160 | 0.080 |
Why?
| | Transcription Factors | 1 | 2017 | 1754 | 0.080 |
Why?
| | Waist-Hip Ratio | 2 | 2009 | 37 | 0.080 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 354 | 0.070 |
Why?
| | Pancreas | 2 | 2023 | 333 | 0.070 |
Why?
| | Bifidobacterium | 2 | 2018 | 21 | 0.070 |
Why?
| | Sequence Analysis, DNA | 3 | 2011 | 823 | 0.070 |
Why?
| | Homeostasis | 2 | 2010 | 641 | 0.070 |
Why?
| | Antigens, Viral | 2 | 2021 | 179 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 99 | 0.070 |
Why?
| | Algorithms | 3 | 2026 | 1818 | 0.070 |
Why?
| | Glycemic Index | 1 | 2008 | 27 | 0.070 |
Why?
| | Isoenzymes | 2 | 2006 | 299 | 0.070 |
Why?
| | Spleen | 1 | 2010 | 517 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2016 | 624 | 0.070 |
Why?
| | Laboratories | 1 | 2009 | 107 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2012 | 781 | 0.070 |
Why?
| | DEAD-box RNA Helicases | 1 | 2008 | 90 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2010 | 374 | 0.070 |
Why?
| | Telomere | 3 | 2022 | 282 | 0.070 |
Why?
| | Disease Outbreaks | 2 | 1991 | 430 | 0.070 |
Why?
| | Antibody Formation | 1 | 2008 | 297 | 0.070 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.070 |
Why?
| | Lipoproteins, LDL | 2 | 2008 | 112 | 0.070 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 24 | 0.070 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 79 | 0.060 |
Why?
| | Clinical Competence | 1 | 2015 | 1237 | 0.060 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 55 | 0.060 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 97 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 2 | 2021 | 566 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1910 | 0.060 |
Why?
| | Antidepressive Agents | 1 | 2009 | 243 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 160 | 0.060 |
Why?
| | Drug Utilization | 2 | 2017 | 166 | 0.060 |
Why?
| | Datasets as Topic | 2 | 2018 | 127 | 0.060 |
Why?
| | Wheat Hypersensitivity | 1 | 2006 | 4 | 0.060 |
Why?
| | Physicians | 1 | 2015 | 940 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2014 | 635 | 0.060 |
Why?
| | Population Surveillance | 3 | 2020 | 489 | 0.060 |
Why?
| | Insulin Infusion Systems | 2 | 2017 | 482 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 30 | 0.060 |
Why?
| | Antibody Specificity | 4 | 2011 | 185 | 0.060 |
Why?
| | Apolipoprotein C-III | 1 | 2006 | 12 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 556 | 0.060 |
Why?
| | Epitope Mapping | 2 | 2024 | 61 | 0.060 |
Why?
| | Birth Order | 2 | 2004 | 13 | 0.060 |
Why?
| | Adenovirus Infections, Human | 1 | 2005 | 16 | 0.060 |
Why?
| | Carrier State | 1 | 2006 | 75 | 0.060 |
Why?
| | Paired Box Transcription Factors | 1 | 2005 | 43 | 0.060 |
Why?
| | Adenoviruses, Human | 1 | 2005 | 28 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 443 | 0.060 |
Why?
| | Receptors, Interleukin-4 | 1 | 2005 | 16 | 0.060 |
Why?
| | Metagenomics | 2 | 2019 | 179 | 0.060 |
Why?
| | Chronic Disease | 4 | 2017 | 1834 | 0.060 |
Why?
| | Codon, Terminator | 1 | 2005 | 25 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 434 | 0.060 |
Why?
| | Chromatography, Liquid | 3 | 2012 | 453 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 78 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 311 | 0.060 |
Why?
| | Codon, Nonsense | 1 | 2005 | 44 | 0.060 |
Why?
| | Protective Factors | 2 | 2015 | 98 | 0.060 |
Why?
| | Capsid Proteins | 1 | 2005 | 97 | 0.060 |
Why?
| | Fathers | 1 | 2005 | 51 | 0.050 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 44 | 0.050 |
Why?
| | Interleukin-13 | 1 | 2005 | 149 | 0.050 |
Why?
| | Norway | 2 | 2019 | 45 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 552 | 0.050 |
Why?
| | CD3 Complex | 1 | 2024 | 110 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4538 | 0.050 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 58 | 0.050 |
Why?
| | Research Design | 3 | 2019 | 1124 | 0.050 |
Why?
| | Survivors | 1 | 2008 | 505 | 0.050 |
Why?
| | Cattle | 3 | 2017 | 990 | 0.050 |
Why?
| | Anthropometry | 1 | 2004 | 208 | 0.050 |
Why?
| | Nutritional Status | 1 | 2007 | 360 | 0.050 |
Why?
| | Pennsylvania | 2 | 2018 | 135 | 0.050 |
Why?
| | Waist Circumference | 2 | 2015 | 137 | 0.050 |
Why?
| | Postmenopause | 3 | 2020 | 377 | 0.050 |
Why?
| | Metagenome | 1 | 2025 | 148 | 0.050 |
Why?
| | Transcriptome | 2 | 2023 | 1029 | 0.050 |
Why?
| | Insulin, Isophane | 1 | 2003 | 21 | 0.050 |
Why?
| | Registries | 7 | 2019 | 2245 | 0.050 |
Why?
| | DNA | 2 | 2011 | 1458 | 0.050 |
Why?
| | Cross-Cultural Comparison | 2 | 2015 | 85 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2004 | 332 | 0.050 |
Why?
| | International Cooperation | 3 | 2016 | 197 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 85 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 335 | 0.050 |
Why?
| | Iron, Dietary | 1 | 2023 | 22 | 0.050 |
Why?
| | Aspartic Acid | 1 | 2023 | 82 | 0.050 |
Why?
| | Peptides, Cyclic | 1 | 2005 | 273 | 0.050 |
Why?
| | Biomedical Research | 1 | 2009 | 699 | 0.050 |
Why?
| | Computer Simulation | 2 | 2026 | 1028 | 0.050 |
Why?
| | Creatine | 1 | 2023 | 63 | 0.050 |
Why?
| | Glycomics | 1 | 2022 | 7 | 0.050 |
Why?
| | Markov Chains | 2 | 2020 | 126 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 127 | 0.050 |
Why?
| | Observer Variation | 2 | 2015 | 361 | 0.050 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2019 | 16 | 0.050 |
Why?
| | Electrocardiography | 2 | 2010 | 630 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2006 | 461 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2009 | 3112 | 0.050 |
Why?
| | Candida | 1 | 2022 | 41 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 477 | 0.050 |
Why?
| | Choline | 1 | 2023 | 133 | 0.050 |
Why?
| | HLA-B15 Antigen | 2 | 2012 | 11 | 0.050 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.040 |
Why?
| | Prenatal Care | 1 | 2004 | 303 | 0.040 |
Why?
| | Consensus | 1 | 2024 | 542 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2005 | 523 | 0.040 |
Why?
| | Electrochemistry | 1 | 2021 | 74 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 390 | 0.040 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2021 | 19 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 44 | 0.040 |
Why?
| | China | 1 | 2021 | 226 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 31 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 54 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 104 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 5 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2025 | 16781 | 0.040 |
Why?
| | Fungi | 1 | 2022 | 156 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 112 | 0.040 |
Why?
| | Perception | 1 | 2023 | 378 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2026 | 884 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 23 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 38 | 0.040 |
Why?
| | Isotopes | 1 | 2020 | 34 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 774 | 0.040 |
Why?
| | Neutrophils | 1 | 2026 | 1134 | 0.040 |
Why?
| | Dehydroascorbic Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 150 | 0.040 |
Why?
| | Antibody Diversity | 1 | 2019 | 16 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 1999 | 13 | 0.040 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2020 | 39 | 0.040 |
Why?
| | Models, Statistical | 3 | 2015 | 686 | 0.040 |
Why?
| | Glucose Transporter Type 2 | 1 | 2019 | 15 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2006 | 698 | 0.040 |
Why?
| | Growth Charts | 1 | 2020 | 20 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 174 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 125 | 0.040 |
Why?
| | Haemophilus influenzae type b | 1 | 1999 | 12 | 0.040 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1999 | 27 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2020 | 57 | 0.040 |
Why?
| | Viral Proteins | 2 | 2006 | 370 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 63 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 76 | 0.040 |
Why?
| | Haemophilus Vaccines | 1 | 1999 | 30 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 204 | 0.040 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2019 | 47 | 0.040 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 1999 | 28 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 607 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 181 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 288 | 0.040 |
Why?
| | Proline | 1 | 2020 | 80 | 0.040 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2019 | 28 | 0.040 |
Why?
| | Efficiency | 1 | 2020 | 101 | 0.040 |
Why?
| | Hepatitis B Vaccines | 1 | 1999 | 47 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 134 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 158 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 132 | 0.040 |
Why?
| | Maternal Behavior | 1 | 1999 | 80 | 0.040 |
Why?
| | Depression | 1 | 2009 | 1514 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 323 | 0.040 |
Why?
| | Texas | 2 | 2014 | 273 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2019 | 191 | 0.040 |
Why?
| | Receptor, Insulin | 1 | 1999 | 94 | 0.040 |
Why?
| | Proteobacteria | 1 | 2018 | 16 | 0.040 |
Why?
| | Alanine | 1 | 2020 | 171 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 427 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 590 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 574 | 0.040 |
Why?
| | Adenoviridae | 1 | 2019 | 205 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 49 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 337 | 0.040 |
Why?
| | Pets | 1 | 2018 | 27 | 0.040 |
Why?
| | Down-Regulation | 1 | 2021 | 644 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 319 | 0.040 |
Why?
| | Emotional Adjustment | 1 | 2018 | 18 | 0.040 |
Why?
| | Lipocalin-2 | 1 | 2018 | 80 | 0.040 |
Why?
| | Alternative Splicing | 1 | 2000 | 243 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Fatty Acids, Volatile | 1 | 2018 | 60 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 252 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2020 | 201 | 0.030 |
Why?
| | Postpartum Period | 1 | 2021 | 354 | 0.030 |
Why?
| | Employment | 1 | 2020 | 182 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 432 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 166 | 0.030 |
Why?
| | Apolipoprotein A-I | 1 | 1997 | 31 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 252 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2938 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 132 | 0.030 |
Why?
| | Loss of Function Mutation | 1 | 2017 | 46 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 143 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2017 | 37 | 0.030 |
Why?
| | Bicarbonates | 1 | 2017 | 45 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2018 | 365 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 461 | 0.030 |
Why?
| | Vitamin E | 1 | 1997 | 123 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2015 | 1051 | 0.030 |
Why?
| | Canada | 1 | 2018 | 434 | 0.030 |
Why?
| | Galactosamine | 1 | 2016 | 3 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 46 | 0.030 |
Why?
| | Biopsy, Needle | 2 | 2011 | 190 | 0.030 |
Why?
| | Lipoprotein(a) | 1 | 1997 | 68 | 0.030 |
Why?
| | Acetylglucosamine | 1 | 2016 | 12 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 526 | 0.030 |
Why?
| | Longevity | 1 | 2018 | 175 | 0.030 |
Why?
| | Molecular Weight | 2 | 2012 | 327 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 370 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 335 | 0.030 |
Why?
| | Africa | 2 | 1996 | 114 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 42 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2017 | 80 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2018 | 504 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 649 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1091 | 0.030 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 14 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2017 | 154 | 0.030 |
Why?
| | Anemia, Sickle Cell | 1 | 2000 | 288 | 0.030 |
Why?
| | Genetic Background | 1 | 2015 | 12 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 308 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 311 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 722 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 80 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1272 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1998 | 498 | 0.030 |
Why?
| | Analysis of Variance | 3 | 2010 | 1314 | 0.030 |
Why?
| | Georgia | 1 | 2015 | 88 | 0.030 |
Why?
| | DNA Primers | 1 | 1996 | 518 | 0.030 |
Why?
| | Genes | 1 | 1995 | 229 | 0.030 |
Why?
| | Radioligand Assay | 2 | 2009 | 37 | 0.030 |
Why?
| | Quality of Life | 2 | 2024 | 3082 | 0.030 |
Why?
| | Florida | 1 | 2015 | 117 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 311 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 435 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 747 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 239 | 0.030 |
Why?
| | Washington | 1 | 2015 | 162 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 678 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 328 | 0.030 |
Why?
| | Airway Management | 1 | 2015 | 79 | 0.030 |
Why?
| | Insulin, Long-Acting | 2 | 2005 | 64 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 144 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 398 | 0.030 |
Why?
| | Tunica Intima | 3 | 2000 | 76 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 142 | 0.030 |
Why?
| | Insulin Glargine | 2 | 2005 | 85 | 0.030 |
Why?
| | Achievement | 1 | 2014 | 59 | 0.030 |
Why?
| | Hospitalization | 1 | 2004 | 2314 | 0.030 |
Why?
| | Epidemiologic Factors | 1 | 2013 | 10 | 0.030 |
Why?
| | Family Characteristics | 1 | 2015 | 192 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 2013 | 50 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2014 | 58 | 0.030 |
Why?
| | Base Sequence | 2 | 2011 | 2200 | 0.020 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2012 | 6 | 0.020 |
Why?
| | Asthma | 1 | 2025 | 1923 | 0.020 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2012 | 11 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2015 | 311 | 0.020 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2012 | 7 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 114 | 0.020 |
Why?
| | Niacinamide | 1 | 1993 | 82 | 0.020 |
Why?
| | S100 Proteins | 1 | 2012 | 36 | 0.020 |
Why?
| | Nurses | 1 | 2015 | 188 | 0.020 |
Why?
| | California | 2 | 2004 | 467 | 0.020 |
Why?
| | Vaccines, Inactivated | 1 | 2012 | 71 | 0.020 |
Why?
| | Biometry | 1 | 1993 | 70 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2015 | 314 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1681 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 152 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 153 | 0.020 |
Why?
| | Nerve Growth Factors | 1 | 2012 | 79 | 0.020 |
Why?
| | Aging | 3 | 2000 | 1955 | 0.020 |
Why?
| | Genome | 1 | 2014 | 309 | 0.020 |
Why?
| | Nitrates | 1 | 1992 | 97 | 0.020 |
Why?
| | Water Supply | 1 | 1992 | 89 | 0.020 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2011 | 14 | 0.020 |
Why?
| | Observation | 1 | 2011 | 56 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2011 | 7 | 0.020 |
Why?
| | Potassium Channels | 1 | 2012 | 145 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 1998 | 928 | 0.020 |
Why?
| | Adenosine Triphosphatases | 1 | 2012 | 160 | 0.020 |
Why?
| | Phylogeny | 2 | 2006 | 1008 | 0.020 |
Why?
| | Ubiquitins | 1 | 2011 | 37 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 50 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2014 | 374 | 0.020 |
Why?
| | Insulinoma | 1 | 2011 | 27 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1505 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 140 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 334 | 0.020 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2011 | 24 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 874 | 0.020 |
Why?
| | Causality | 1 | 1991 | 132 | 0.020 |
Why?
| | Leptin | 1 | 2012 | 239 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2007 | 702 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2015 | 575 | 0.020 |
Why?
| | Brain | 1 | 2023 | 2899 | 0.020 |
Why?
| | Endothelium, Vascular | 2 | 2008 | 962 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 13 | 0.020 |
Why?
| | Biostatistics | 1 | 2009 | 18 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2009 | 30 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 251 | 0.020 |
Why?
| | Fetal Weight | 1 | 2009 | 54 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 44 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 151 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8077 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 98 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 404 | 0.020 |
Why?
| | Pancreatic Polypeptide | 1 | 1989 | 4 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 2009 | 94 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 527 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 846 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2008 | 29 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 46 | 0.020 |
Why?
| | Tunica Media | 2 | 2000 | 36 | 0.020 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2008 | 21 | 0.020 |
Why?
| | Protein Precursors | 1 | 2009 | 135 | 0.020 |
Why?
| | Survival Rate | 2 | 2006 | 2008 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 141 | 0.020 |
Why?
| | Telecommunications | 1 | 1988 | 21 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2009 | 197 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2008 | 30 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1483 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2008 | 36 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2000 | 994 | 0.020 |
Why?
| | Pacific Islands | 1 | 1988 | 3 | 0.020 |
Why?
| | Solanum tuberosum | 1 | 2008 | 7 | 0.020 |
Why?
| | Outpatients | 1 | 1992 | 426 | 0.020 |
Why?
| | Probability | 1 | 1989 | 308 | 0.020 |
Why?
| | Glucagon | 1 | 1989 | 111 | 0.020 |
Why?
| | Americas | 1 | 1988 | 26 | 0.020 |
Why?
| | Asia | 1 | 1988 | 67 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 97 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 2009 | 124 | 0.020 |
Why?
| | Survival | 1 | 2007 | 38 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 20 | 0.020 |
Why?
| | Carotenoids | 1 | 2007 | 42 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 163 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 186 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1736 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 47 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2006 | 72 | 0.020 |
Why?
| | 5' Untranslated Regions | 1 | 2006 | 61 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2006 | 58 | 0.020 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2006 | 64 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1477 | 0.020 |
Why?
| | Serotyping | 1 | 2005 | 33 | 0.010 |
Why?
| | Self Care | 1 | 2009 | 388 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2006 | 367 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2013 | 2854 | 0.010 |
Why?
| | Species Specificity | 1 | 2006 | 577 | 0.010 |
Why?
| | Alprostadil | 1 | 2005 | 32 | 0.010 |
Why?
| | Cause of Death | 2 | 2002 | 461 | 0.010 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2005 | 136 | 0.010 |
Why?
| | Puerto Rico | 1 | 2004 | 54 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 377 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 642 | 0.010 |
Why?
| | Dinoprostone | 1 | 2005 | 182 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2004 | 11389 | 0.010 |
Why?
| | Ultrasonography | 2 | 2000 | 773 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 122 | 0.010 |
Why?
| | Genome, Viral | 1 | 2005 | 224 | 0.010 |
Why?
| | Regeneration | 1 | 2005 | 198 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2003 | 94 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 294 | 0.010 |
Why?
| | Insulin Lispro | 1 | 2003 | 42 | 0.010 |
Why?
| | Mutation | 1 | 2015 | 4059 | 0.010 |
Why?
| | DNA, Viral | 1 | 2005 | 366 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2008 | 2194 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2005 | 270 | 0.010 |
Why?
| | Duodenum | 1 | 2003 | 77 | 0.010 |
Why?
| | Health | 1 | 2003 | 83 | 0.010 |
Why?
| | Income | 1 | 2003 | 198 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2002 | 56 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 101 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 213 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4183 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2000 | 83 | 0.010 |
Why?
| | Carotid Artery, Internal | 1 | 2000 | 44 | 0.010 |
Why?
| | Carotid Artery, Common | 1 | 2000 | 31 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 277 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 1985 | 513 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 1999 | 5 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 1015 | 0.010 |
Why?
| | Genetic Counseling | 1 | 1999 | 82 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5220 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 1999 | 163 | 0.010 |
Why?
| | Twins, Monozygotic | 1 | 1999 | 192 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1998 | 167 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 274 | 0.010 |
Why?
| | Demography | 1 | 1998 | 297 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1218 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2621 | 0.010 |
Why?
| | Quantitative Trait, Heritable | 1 | 1997 | 124 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 1998 | 363 | 0.010 |
Why?
| | Bacterial Infections | 1 | 1998 | 246 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1998 | 422 | 0.010 |
Why?
| | Mexico | 1 | 1996 | 230 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2000 | 2531 | 0.010 |
Why?
| | Mental Disorders | 1 | 2002 | 1151 | 0.010 |
Why?
| | Baltic States | 1 | 1992 | 1 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1998 | 942 | 0.010 |
Why?
| | Rats | 1 | 2000 | 5611 | 0.010 |
Why?
| | Geography | 1 | 1992 | 202 | 0.010 |
Why?
| | Software | 1 | 1997 | 687 | 0.010 |
Why?
| | Cohort Effect | 1 | 1990 | 4 | 0.010 |
Why?
| | Periodicity | 1 | 1990 | 56 | 0.000 |
Why?
| | Space-Time Clustering | 1 | 1989 | 3 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1989 | 22 | 0.000 |
Why?
| | Coxsackievirus Infections | 1 | 1987 | 14 | 0.000 |
Why?
| | Rubella | 1 | 1987 | 23 | 0.000 |
Why?
| | Mortality | 1 | 1989 | 364 | 0.000 |
Why?
| | Neoplasms | 1 | 1989 | 2809 | 0.000 |
Why?
|
|
Rewers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|